QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck
QIAGEN N.V. has entered a strategic collaboration with BioNTech SE to develop a tissue-based companion diagnostic for identifying patients with head and neck squamous cell carcinoma (SCCHN) linked to human papilloma virus (HPV) infections. Utilizing QIAGEN’s RGQ MDx platform, the assay aims to expand its applications across various HPV-related cancers. With over 650,000 new SCCHN cases annually, and projections indicating doubled numbers by 2035, this collaboration positions QIAGEN to enhance its HPV diagnostic offerings, building on its established market leadership.
- Strategic collaboration with BioNTech SE to develop a companion diagnostic for HPV-related SCCHN.
- Utilization of QIAGEN's RGQ MDx platform to develop advanced diagnostic tools.
- Expansion of HPV diagnostic offerings to potentially cover more cancer types, enhancing market presence.
- None.
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration with BioNTech SE (Nasdaq: BNTX) to develop and commercialize a tissue-based companion diagnostic – to be used with investigational cancer treatment BNT113 – which identifies patients with squamous cell carcinoma of the head and neck (SCCHN) that are caused by specific infections by human papilloma virus (HPV).
The assay will detect the presence of HPV genotypes and will be developed on QIAGEN´s RGQ MDx platform, a member of the QIAsymphony family of products.
QIAGEN plans to expand the panel for use across HPV-driven cancers such as cervical cancer and other cancers, in order to provide a universal HPV companion diagnostic (CDx) for QIAGEN’s pharmaceutical partners.
Head and neck squamous cell carcinoma is the sixth most common cancer. Every year, there are more than 650,000 cases leading to 330,000 deaths, according to a 2018 global cancer study. These numbers are expected to double by 2035, according to the World Health Organization. The incidence of HPV-related SCCHN has significantly increased in recent years.
QIAGEN established the global HPV testing market over two decades ago. More than 100 million women have been tested for HPV infections using QIAGEN´s portfolio of HPV products, including hybrid capture, genotyping, and methylation tests.
Please find the full press release here
